In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes

Circulation

Volumn 122, Issue 16, 2010, Pages 1578-1587

  Britton, George L ^a   Kim, Hyunggun ^a   Kee, Patrick H ^a   Aronowski, Jaroslaw ^a   Holland, Christy K ^b   McPherson, David D ^a   Huang, Shao Ling ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

cerebral ischemia; contrast media; liposomes; stroke; xenon

Indexed keywords

GLUCOSE; LIPOSOME; OXYGEN; XENON;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; IN VITRO STUDY; INTERNAL CAROTID ARTERY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRASOUND; ANIMAL; BRAIN ISCHEMIA; CELL SURVIVAL; CEREBRAL ARTERY DISEASE; CYTOLOGY; ECHOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; PHYSIOLOGY; REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ANIMALS; BRAIN ISCHEMIA; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; LIPOSOMES; MALE; MODELS, ANIMAL; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; ULTRASONOGRAPHY; XENON;

EID: 78049497801     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.879338     Document Type: Article

References (42)

1. Suwanwela NC, Eusattasak N, Phanthumchinda K, Piravej K, Locharoenkul C. Combination of acute stroke unit and short-term stroke ward with early supported discharge decreases mortality and complications after acute ischemic stroke. J Med Assoc Thai. 2007;90:1089-1096.
2. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets. 2008;7:243-253.
3. Goldstein LB, Rothwell PM. Primary prevention and health services delivery. Stroke. 2007;38:222-224.
4. Wagner KR, Jauch EC. Extending the window for acute stroke treatment: thrombolytics plus CNS protective therapies. Exp Neurol. 2004;188:195-199.
5. Catarzi D, Colotta V, Varano F. Competitive Gly/NMDA receptor antagonists. Curr Top Med Chem. 2006;6:809-821.
6. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7:742-755.
7. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets. 2007;8:621-632.
8. Parsons CG, Danysz W, Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 1998;11:523-569.
9. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 2000;31:347-354.
10. Olney JW, Ikonomidou C, Mosinger JL, Frierdich G. MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain. J Neurosci. 1989;9:1701-1704.
11. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515-1518.
12. Arrowsmith JE, Harrison MJ, Newman SP, Stygall J, Timberlake N, Pugsley WB. Neuroprotection of the brain during cardiopulmonary bypass: a randomized trial of remacemide during coronary artery bypass in 171 patients. Stroke. 1998;29:2357-2362.
13. Derwall M, Coburn M, Rex S, Hein M, Rossaint R, Fries M. Xenon: recent developments and future perspectives. Minerva Anestesiol. 2009;75:37-45.
14. David HN, Ansseau M, Lemaire M, Abraini JH. Nitrous oxide and xenon prevent amphetamine-induced carrier-mediated dopamine release in a memantine-like fashion and protect against behavioral sensitization. Biol Psychiatry. 2006;60:49-57.
15. Dworschak M. Pharmacologic neuroprotection: is xenon the light at the end of the tunnel? Crit Care Med. 2008;36:2477-2479.
16. Fries M, Nolte KW, Coburn M, Rex S, Timper A, Kottmann K, Siepmann K, Hausler M, Weis J, Rossaint R. Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med. 2008;36:2420-2426.
17. Ma J, Zhang GY. Lithium reduced N-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. Neurosci Lett. 2003;348:185-189.
18. Palmer GC, Widzowski D. Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids. 2000;19:151-155.
19. Petzelt C, Blom P, Schmehl W, Muller J, Kox WJ. Prevention of neurotoxicity in hypoxic cortical neurons by the noble gas xenon. Life Sci. 2003;72:1909-1918.
20. Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels: comparison with isoflurane and ethanol. Anesthesiology. 2000;93:1095-1101.
21. Huang SL, Kee PH, Kim H, Moody MR, Chrzanowski SM, Macdonald RC, McPherson DD. Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia. J Am Coll Cardiol. 2009;54:652-659.
22. Britton GL, Kee PH, McPherson DD, Huang SL. Novel drug delivery for neuroprotection against ischemic insults. Ann Neurol. 2008;64:S13.
23. Huang SL, Hamilton AJ, Pozharski E, Nagaraj A, Klegerman ME, McPherson DD, MacDonald RC. Physical correlates of the ultrasonic reflectivity of lipid dispersions suitable as diagnostic contrast agents. Ultrasound Med Biol. 2002;28:339-348.
24. Zhao X, Sun G, Zhang J, Strong R, Song W, Gonzales N, Grotta JC, Aronowski J. Hematoma resolution as a target for intracerebral hemorrhage treatment: role for peroxisome proliferator-activated receptor gamma in microglia/macrophages. Ann Neurol. 2007;61:352-362.
25. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
26. Wahlgren NG, Diez-Tejedor E, Teitelbaum J, Arboix A, Leys D, Ashwood T, Grossman E. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients. Stroke. 2000;31:82-85.
27. Zhao X, Liu SJ, Zhang J, Strong R, Aronowski J, Grotta JC. Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats. Stroke. 2005;36:129-134.
28. Siegel S, Castellan NJ. Nonparametric Statistics for the Behavioral Sciences. 2nd ed. New York, NY: McGraw-Hill; 1988:213-215.
29. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008;55:363-389.
30. Fisher M, Ratan R. New perspectives on developing acute stroke therapy. Ann Neurol. 2003;53:10-20.
31. Ladefoged J, Andersen AM. Solubility of xenon-133 at 37°C in water, saline, olive oil, liquid paraffin, solutions of albumin, and blood. Phys Med Biol. 1967;12:353.
32. Yeh SY, Peterson RE. Solubility of carbon dioxide, krypton, and xenon in lipids. J Pharmacol Sci. 1963;52:453-458.
33. Klegerman ME, Zou Y, McPherson DD. Fibrin targeting of echogenic liposomes with inactivated tissue plasminogen activator. J Liposome Res. 2008;18:95-112.
34. Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res. 2009;124:306-310.
35. Tiukinhoy-Laing SD, Huang S, Klegerman M, Holland CK, McPherson DD. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb Res. 2007;119:777-784.
36. Datta S, Coussios CC, Ammi AY, Mast TD, de Courten-Myers GM, Holland CK. Ultrasound-enhanced thrombolysis using Definity as a cavitation nucleation agent. Ultrasound Med Biol. 2008;34:1421-1433.
37. Juttler E, Kohrmann M, Schellinger PD. Therapy for early reperfusion after stroke. Nat Clin Pract Cardiovasc Med. 2006;3:656-663.
38. Brisman JL, Eskridge JM, Newell DW. Neurointerventional treatment of vasospasm. Neurol Res. 2006;28:769-776.
39. Smith DA, Porter TM, Martinez J, Huang S, MacDonald RC, McPherson DD, Holland CK. Destruction thresholds of echogenic liposomes with clinical diagnostic ultrasound. Ultrasound Med Biol. 2007;33:797-809.
40. Franks NP, Dickinson R, de Sousa SL, Hall AC, Lieb WR. How does xenon produce anaesthesia? Nature. 1998;396:324.
41. Jevtovic-Todorovic V, Todorovic SM, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski CF, Olney JW. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998;4:460-463.
42. Ma D, Yang H, Lynch J, Franks NP, Maze M, Grocott HP. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology. 2003;98:690-698.